聖湘生物(688289.SH)將於8月28日在科創板上市
格隆匯 8 月 26日丨聖湘生物(688289.SH)發佈首次公開發行股票科創板上市公告書,發行數量4000萬股,無老股轉讓;發行價50.48元/股;將於2020年8月28日在上海證券交易所上市。
市盈率536.30倍(發行價格除以每股收益,每股收益按照2019年經審計的扣除非經常性損益前後孰低的歸屬於母公司股東的淨利潤除以本次發行後總股本計算)
結合行業發展趨勢及公司實際經營情況,公司預計2020年1-9月可實現營業收入299,601.12萬元,與上年同期相比增長1131.11%;預計2020年1-9月可實現扣除非經常性損益後的歸屬於母公司股東的淨利潤為172,941.08 萬元,與上年同期相比增長13457.15%,業績快速增長。上述2020年1-9月財務數據為公司預計數據,不構成盈利預測。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.